Page last updated: 2024-10-28

hydralazine and Fibrosis

hydralazine has been researched along with Fibrosis in 34 studies

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.

Research Excerpts

ExcerptRelevanceReference
" Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect."8.12Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022)
"Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis."8.02Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021)
" Here, we aimed to determine whether lowering blood pressure with hydralazine might prevent inflammation and cardiac fibrosis in response to angiotensin II."7.77Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. ( Bian, Y; Cheng, J; Du, J; Jia, L; Li, H; Li, Y; Qi, G; Xiao, C, 2011)
" To determine if the TI injury accompanying cyclosporine A (CsA) nephropathy was associated with accelerated apoptosis and ischemia, we treated rats for five weeks with CsA with or without losartan (to block angiotensin II type 1 receptor), or hydralazine/furosemide (H/F) (protocol #1)."7.70Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. ( Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE, 1998)
" In this study, we evaluated the postinfarction survival, susceptibility to ventricular arrhythmias, and degree of LVH and cardiac fibrosis in the spontaneously hypertensive rat (SHR) and the effects of the ACE inhibitor ramipril and the direct vasodilator hydralazine on these characteristics."7.70Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine. ( El Salibi, E; Nguyen, T; Rouleau, JL, 1998)
"Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor."5.91Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023)
"However, cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression, was inhibited by only Olm treatment, but not by Hyd."5.43Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. ( Ichikawa, H; Kimura, Y; Kinjo, T; Narita, I; Nishizaki, K; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H, 2016)
" Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect."4.12Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022)
"Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis."4.02Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021)
"The infusion of chronic angiotensin II (Ang II) has been shown to promote renal interstitial fibrosis."3.81Aggravated renal tubular damage and interstitial fibrosis in mice lacking guanylyl cyclase-A (GC-A), a receptor for atrial and B-type natriuretic peptides. ( Horio, T; Kangawa, K; Kawano, Y; Kishimoto, I; Kuwabara, A; Otani, K; Tokudome, T; Yoshihara, F, 2015)
" Although both tempol and candesartan effectively reduced reactive oxygen species production in the kidney, tempol did not decrease blood pressure and exacerbated urine protein and histological damage, such as glomerulosclerosis and interstitial fibrosis, particularly in juxtamedullary nephrons (tempol vs."3.80Superoxide dismutase mimetic, tempol, aggravates renal injury in advanced-stage stroke-prone spontaneously hypertensive rats. ( Kohagura, K; Nakamura, T; Ohya, Y; Shinzato, T; Sugama, I; Yamazato, M, 2014)
" Here, we aimed to determine whether lowering blood pressure with hydralazine might prevent inflammation and cardiac fibrosis in response to angiotensin II."3.77Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. ( Bian, Y; Cheng, J; Du, J; Jia, L; Li, H; Li, Y; Qi, G; Xiao, C, 2011)
" One week after disease induction, animals were randomly assigned to chronic glomerulosclerosis, chronic glomerulosclerosis plus Bay 41-2272 (10 mg/kg body weight/day) or chronic glomerulosclerosis plus hydralazine (15 mg/kg body weight/day)."3.73Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. ( Kawachi, H; Krämer, S; Kron, S; Loof, T; Martini, S; Neumayer, HH; Peters, H; Shimizu, F; Wang, Y, 2005)
" To determine if the TI injury accompanying cyclosporine A (CsA) nephropathy was associated with accelerated apoptosis and ischemia, we treated rats for five weeks with CsA with or without losartan (to block angiotensin II type 1 receptor), or hydralazine/furosemide (H/F) (protocol #1)."3.70Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. ( Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE, 1998)
" In this study, we evaluated the postinfarction survival, susceptibility to ventricular arrhythmias, and degree of LVH and cardiac fibrosis in the spontaneously hypertensive rat (SHR) and the effects of the ACE inhibitor ramipril and the direct vasodilator hydralazine on these characteristics."3.70Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine. ( El Salibi, E; Nguyen, T; Rouleau, JL, 1998)
" However, although chronic enalapril and hydralazine protect against the loss of renal function, only enalapril limits renal growth and proteinuria, and neither significantly limits tubulointerstitial fibrosis."3.70Hypertension and renal injury in experimental polycystic kidney disease. ( Al-Nimri, MA; Anderson, S; Chapman, JG; Kelly, FJ; Kennefick, TM; Oyama, TT; Thompson, MM, 1999)
"Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor."1.91Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023)
"However, cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression, was inhibited by only Olm treatment, but not by Hyd."1.43Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression. ( Ichikawa, H; Kimura, Y; Kinjo, T; Narita, I; Nishizaki, K; Okumura, K; Osanai, T; Tanaka, M; Tanno, T; Tomita, H, 2016)
"Renal fibrosis was increased 2."1.42A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression. ( Bin, W; Cao, W; Hou, FF; Li, A; Su, Z; Wang, L; Wilcox, CS; Zhou, Z, 2015)
"Hydralazine did not affect cardiac hypertrophy in wild-type mice and mice lacking either AT(1) or AT(2) receptors alone."1.36Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A. ( Harada, M; Horiuchi, M; Kishimoto, I; Kuwahara, K; Li, Y; Murray, M; Nakao, K; Rong, X; Saito, Y, 2010)
"Olmesartan was associated with a significantly reduced myocyte hypertrophy index (4."1.36Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan. ( Hatipoglu, FO; Hirohata, S; Iwamoto, M; Kusachi, S; Miyoshi, T; Ninomiya, Y; Ogawa, H; Ohtsuki, T; Shinohata, R; Yamamoto, K, 2010)
"Renal fibrosis is one of the major complications associated with the development of hypertension."1.32Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. ( Boffa, JJ; Chatziantoniou, C; Dussaule, JC; Lu, Y; Placier, S; Stefanski, A, 2003)
"Cardiac hypertrophy was also observed after chronic inhibition of nitric oxide synthesis."1.29Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. ( Egashira, K; Kadokami, T; Numaguchi, K; Shimokawa, H; Sueishi, K; Takemoto, M; Takeshita, A, 1995)

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.94)18.7374
1990's5 (14.71)18.2507
2000's10 (29.41)29.6817
2010's14 (41.18)24.3611
2020's4 (11.76)2.80

Authors

AuthorsStudies
Larkin, BP2
Nguyen, LT2
Hou, M2
Glastras, SJ2
Chen, H2
Faiz, A1
Chen, J1
Wang, R2
Pollock, CA2
Saad, S2
Chiang, CH1
Chen, C1
Fang, SY1
Lin, SC1
Chen, JW1
Chang, TT1
Hayashi, K1
Shimokawa, T1
Yamagata, M1
Yoneda, K1
Sogawa, Y1
Nagasu, H1
Itano, S1
Kidokoro, K1
Taniguchi, S1
Takahashi, M1
Kadoya, H1
Satoh, M1
Sasaki, T1
Kashihara, N1
Sugama, I1
Kohagura, K1
Yamazato, M1
Nakamura, T2
Shinzato, T1
Ohya, Y1
Yoshihara, F1
Tokudome, T1
Kishimoto, I3
Otani, K1
Kuwabara, A1
Horio, T1
Kawano, Y1
Kangawa, K1
Cao, W1
Li, A1
Wang, L1
Zhou, Z1
Su, Z1
Bin, W1
Wilcox, CS1
Hou, FF1
Ueda, M1
Uchimura, K1
Narita, Y1
Miyasato, Y1
Mizumoto, T1
Morinaga, J1
Hayata, M1
Kakizoe, Y1
Adachi, M1
Miyoshi, T2
Shiraishi, N1
Kadowaki, D1
Sakai, Y1
Mukoyama, M1
Kitamura, K1
Tanno, T1
Tomita, H1
Narita, I1
Kinjo, T1
Nishizaki, K1
Ichikawa, H1
Kimura, Y1
Tanaka, M1
Osanai, T1
Okumura, K1
Tampe, B1
Steinle, U1
Tampe, D1
Carstens, JL1
Korsten, P1
Zeisberg, EM1
Müller, GA1
Kalluri, R1
Zeisberg, M1
Zamani, P1
Akers, S1
Soto-Calderon, H1
Beraun, M1
Koppula, MR1
Varakantam, S1
Rawat, D1
Shiva-Kumar, P1
Haines, PG1
Chittams, J1
Townsend, RR1
Witschey, WR1
Segers, P1
Chirinos, JA1
Wilson, RM1
De Silva, DS1
Sato, K1
Izumiya, Y1
Sam, F1
Li, Y4
Saito, Y2
Kuwahara, K2
Rong, X1
Harada, M2
Horiuchi, M1
Murray, M1
Nakao, K2
Ferreira, DN1
Katayama, IA1
Oliveira, IB1
Rosa, KT1
Furukawa, LN1
Coelho, MS1
Casarini, DE1
Heimann, JC1
Leelahavanichkul, A1
Yan, Q1
Hu, X1
Eisner, C1
Huang, Y1
Chen, R1
Mizel, D1
Zhou, H1
Wright, EC1
Kopp, JB1
Schnermann, J1
Yuen, PS1
Star, RA1
Iwamoto, M1
Hirohata, S1
Ogawa, H1
Ohtsuki, T1
Shinohata, R1
Hatipoglu, FO1
Kusachi, S1
Yamamoto, K1
Ninomiya, Y1
Qi, G1
Jia, L1
Bian, Y1
Cheng, J1
Li, H1
Xiao, C1
Du, J1
Villa, L1
Boor, P1
Konieczny, A1
Kunter, U1
van Roeyen, CR1
Denecke, B1
Gan, L1
Neusser, MA1
Cohen, CD1
Eitner, F1
Scholl, T1
Ostendorf, T1
Floege, J1
Boffa, JJ1
Lu, Y1
Placier, S1
Stefanski, A1
Dussaule, JC1
Chatziantoniou, C1
DANIEL-MOUSSARD, H1
COLLET, A1
Endemann, DH1
Touyz, RM1
Iglarz, M1
Savoia, C1
Schiffrin, EL1
Wang, Y1
Krämer, S1
Loof, T1
Martini, S1
Kron, S1
Kawachi, H1
Shimizu, F1
Neumayer, HH1
Peters, H1
Nakanishi, M1
Takahashi, N1
Kawakami, R1
Nakagawa, Y1
Tanimoto, K1
Yasuno, S1
Usami, S1
Adachi, Y1
Fukamizu, A1
Garbers, DL1
Nagase, M1
Shibata, S1
Yoshida, S1
Nagase, T1
Gotoda, T1
Fujita, T1
Takemura, G1
Okada, H1
Miyata, S1
Kanamori, H1
Maruyama, R1
Esaki, M1
Li, L1
Ogino, A1
Ohno, T1
Kondo, T1
Nakagawa, M1
Minatoguchi, S1
Fujiwara, T1
Fujiwara, H1
Vellaichamy, E1
Zhao, D1
Somanna, N1
Pandey, KN1
Shi, YX1
Chen, Y1
Zhu, YZ1
Huang, GY1
Moore, PK1
Huang, SH1
Yao, T1
Zhu, YC1
Numaguchi, K1
Egashira, K1
Takemoto, M1
Kadokami, T1
Shimokawa, H1
Sueishi, K1
Takeshita, A1
Ikeda, K1
Nara, Y1
Tagami, M1
Yamori, Y1
Thomas, SE1
Andoh, TF1
Pichler, RH1
Shankland, SJ1
Couser, WG1
Bennett, WM1
Johnson, RJ1
Nguyen, T1
El Salibi, E1
Rouleau, JL1
Kennefick, TM1
Al-Nimri, MA1
Oyama, TT1
Thompson, MM1
Kelly, FJ1
Chapman, JG1
Anderson, S1
Ikeda, Y1
Takano, H1
Kimura, H1
Obata, JE1
Takeda, S1
Hata, A1
Shido, K1
Mochizuki, S1
Yoshida, Y1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction[NCT01516346]Phase 244 participants (Actual)Interventional2012-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Early Diastolic Mitral Annular Velocity

Diastolic mitral annular velocity measured at the basal septal mitral annulus (NCT01516346)
Timeframe: 24 weeks

Interventioncm/s (Mean)
Isosorbide Dinitrate6.8
Isosorbide Dinitrate + Hydralazine7.3
Placebo6.5

LV Mass

LV mass measured by MRI, in grams normalized to height in meters raised to the 1.7 power (m^1.7) (NCT01516346)
Timeframe: 24 weeks

Interventiongrams / meters ^1.7 (Mean)
Isosorbide Dinitrate68.2
Isosorbide Dinitrate + Hydralazine66.2
Placebo67.2

Myocardial Extracellular Volume Fraction

Myocardial extracellular volume, expressed as percent of total tissue volume, measured by MRI (T1 mapping pre and post-gadolinium administration) (NCT01516346)
Timeframe: 24 weeks

InterventionPercentage (Mean)
Isosorbide Dinitrate29.0
Isosorbide Dinitrate + Hydralazine31.3
Placebo29.5

Quality of Life (Kansas City Cardiomyopathy Questionnaire Score)

Quality of life, assessed with the Kansas City cardiomyopathy questionnaire (overall summary score, which ranges from 0 to 100). Higher values imply better quality of life. (NCT01516346)
Timeframe: 24 weeks

InterventionPoints on a scale (Mean)
Isosorbide Dinitrate62.1
Isosorbide Dinitrate + Hydralazine44.9
Placebo62.1

Wave Reflection Magnitude

The dimensionless ratio of backward (reflected) to forward wave amplitude. Higher values imply more wave reflection. (NCT01516346)
Timeframe: 24 weeks

Interventiondimensionless ratio (Mean)
Isosorbide Dinitrate0.38
Isosorbide Dinitrate + Hydralazine0.44
Placebo0.37

Trials

1 trial available for hydralazine and Fibrosis

ArticleYear
Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.
    Journal of the American Heart Association, 2017, 02-20, Volume: 6, Issue:2

    Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Echocardiogr

2017

Other Studies

33 other studies available for hydralazine and Fibrosis

ArticleYear
Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:10

    Topics: Albuminuria; Animals; Diet, High-Fat; Disease Models, Animal; Fibrosis; Hydralazine; Inflammation; K

2022
Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease.
    Life sciences, 2023, Aug-15, Volume: 327

    Topics: Acute Kidney Injury; Animals; Enzyme Inhibitors; Fibrosis; Humans; Hydralazine; Inflammation; Kidney

2023
Inhibition of α
    Journal of pharmacological sciences, 2021, Volume: 145, Issue:1

    Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blister; Disease Models, Animal; Disease Progressi

2021
Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet.
    PloS one, 2021, Volume: 16, Issue:3

    Topics: Albuminuria; Animals; Biomarkers; Body Weight; Collagen; Diet, High-Fat; DNA Methylation; Female; Fi

2021
The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice.
    PloS one, 2018, Volume: 13, Issue:10

    Topics: Aldosterone; Animals; Antihypertensive Agents; Disease Models, Animal; Endothelium; Fibrosis; Humans

2018
Superoxide dismutase mimetic, tempol, aggravates renal injury in advanced-stage stroke-prone spontaneously hypertensive rats.
    Journal of hypertension, 2014, Volume: 32, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Benzimidazo

2014
Aggravated renal tubular damage and interstitial fibrosis in mice lacking guanylyl cyclase-A (GC-A), a receptor for atrial and B-type natriuretic peptides.
    Clinical and experimental nephrology, 2015, Volume: 19, Issue:2

    Topics: Actins; Angiotensin II; Animals; Antigens, Differentiation; Antihypertensive Agents; Atrophy; Blood

2015
A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression.
    Journal of the American Society of Nephrology : JASN, 2015, Volume: 26, Issue:7

    Topics: Analysis of Variance; Animals; Blotting, Western; Brain; Disease Models, Animal; Disease Progression

2015
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
    Nephron, 2015, Volume: 129, Issue:3

    Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Est

2015
Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression.
    Journal of cardiovascular pharmacology, 2016, Volume: 67, Issue:6

    Topics: Animals; Blood Pressure; Cardiomegaly; Fibrosis; Gene Expression; Hydralazine; Imidazoles; Male; Mic

2016
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.
    Kidney international, 2017, Volume: 91, Issue:1

    Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Animals; CpG Islands; Dioxygenases; D

2017
Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.
    Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:3

    Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cytokines; Diastole; Drug Therapy,

2009
Vasodilator therapy with hydralazine induces angiotensin AT receptor-mediated cardiomyocyte growth in mice lacking guanylyl cyclase-A.
    British journal of pharmacology, 2010, Volume: 159, Issue:5

    Topics: Animals; Blood Pressure; Cardiomegaly; Fibrosis; Gene Expression; Hydralazine; Male; Mice; Mice, Inb

2010
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
    The Journal of nutrition, 2010, Volume: 140, Issue:10

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen

2010
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.
    Kidney international, 2010, Volume: 78, Issue:11

    Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens

2010
Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:12

    Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Car

2010
Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent.
    Cardiovascular toxicology, 2011, Volume: 11, Issue:2

    Topics: Angiotensin II; Animals; Blood Pressure; Fibrosis; Hydralazine; Hypertrophy, Left Ventricular; Infla

2011
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
    The Journal of pathology, 2013, Volume: 229, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles;

2013
Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases.
    Journal of the American Society of Nephrology : JASN, 2003, Volume: 14, Issue:5

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Collagen; Enzyme

2003
[Influence of complex agents on the development of experimental fibrosis induced by silica in the rat].
    Revue francaise d'etudes cliniques et biologiques, 1960, Volume: 5

    Topics: Animals; Dimercaprol; Edetic Acid; Fibrosis; Hydralazine; Rats; Silicon Dioxide; Silicosis

1960
Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:6

    Topics: Acetylcholine; Aldosterone; Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Collagen

2004
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
    Kidney international, 2005, Volume: 68, Issue:1

    Topics: Animals; Biomarkers; Blood Pressure; Body Weight; Chronic Disease; Disease Progression; Eating; Enzy

2005
Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice.
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 46, Issue:2

    Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cause of Death; Diuresi

2005
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
    Hypertension (Dallas, Tex. : 1979), 2006, Volume: 47, Issue:6

    Topics: Animals; Apoptosis; Biomarkers; Blood Pressure; Eplerenone; Fibrosis; Glomerulosclerosis, Focal Segm

2006
ANG II type 1A receptor signaling causes unfavorable scar dynamics in the postinfarct heart.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 292, Issue:2

    Topics: Androstadienes; Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Cell Proliferation; Fib

2007
Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: role in cardiac hypertrophy.
    Physiological genomics, 2007, Oct-22, Volume: 31, Issue:2

    Topics: Angiotensin II; Animals; Captopril; Cardiomegaly; Cyclic GMP; Fibrosis; Gene Expression Regulation;

2007
Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:4

    Topics: Animals; Antihypertensive Agents; Blood Chemical Analysis; Blood Pressure; Cardiomegaly; Cardiotonic

2007
Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats.
    Hypertension (Dallas, Tex. : 1979), 1995, Volume: 26, Issue:6 Pt 1

    Topics: Animals; Arginine; Blood Pressure; Cardiomegaly; Coronary Circulation; Coronary Vessels; Data Interp

1995
Nitric oxide deficiency induces myocardial infarction in hypercholesterolaemic stroke-prone spontaneously hypertensive rats.
    Clinical and experimental pharmacology & physiology, 1997, Volume: 24, Issue:5

    Topics: Animals; Blood Pressure; Cerebrovascular Disorders; Coronary Vessels; Enzyme Inhibitors; Fibrosis; H

1997
Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.
    Kidney international, 1998, Volume: 53, Issue:4

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Apoptosis; Argin

1998
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.
    Circulation, 1998, Nov-10, Volume: 98, Issue:19

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiac Pac

1998
Hypertension and renal injury in experimental polycystic kidney disease.
    Kidney international, 1999, Volume: 56, Issue:6

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Enalapril; Fibrosis; Hydralazine; Hypertension, Re

1999
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
    The Journal of laboratory and clinical medicine, 2000, Volume: 135, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv

2000